FDA lifts a partial clinical hold on Avidity Biosciences’ delpacibart etedesiran (del-desiran/AOC 1001) that is being evaluated for treating myotonic dystrophy Type 1.
FDA denies an Amneal Pharmaceuticals petition asking the agency to take several actions involving Provell’s Euthyrox (levothyroxine sodium).
FDA lifts a partial clinical hold on Avidity Biosciences’ delpacibart etedesiran (del-desiran/AOC 1001) that is being evaluated for treating myotonic dystrophy Type 1.
FDA denies an Amneal Pharmaceuticals petition asking the agency to take several actions involving Provell’s Euthyrox (levothyroxine sodium).
FDA says the shortage of Lilly’s Mounjaro and Zepbound has been resolved but other similar products remain in short supply.
FDA clears an OrthAlign 510(k) for its Lantern Hip handheld technology for direct anterior total hip arthroplasty in patients in the supine position.
